Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: A systematic review and meta-analysis
PLOS ONE · 31.03.2023 · 18 (3) · e0278356
DOI: 10.1371/journal.pone.0278356 ↗Kurz gefasst
Metaanalyse in der Zeitschrift PLOS ONE, online erschienen am 31.03.2023. Verfasst von Julie Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, Nova Scotia, Canada. Hauptthemen laut MEDLINE: COVID-19, Probiotics. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Oral probiotic supplementation may be a beneficial adjunctive therapy for patients with symptomatic COVID-19. However, its safety and efficacy are unclear. We aimed to investigate how probiotic supplementation impacts COVID-19 symptom trajectory and patient outcomes by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).
Methods
RCTs randomizing patients with COVID-19 to probiotics were searched in PubMed Central, Embase, CINAHL, and Cochrane Library from inception to July 31, 2022. We performed a random-effects pairwise meta-analysis for all outcomes using the restricted maximum likelihood (REML) estimator. We used the GRADE approach to assess the certainty of the evidence.
Results
A total of 1027 participants from eight RCT studies were included in the meta-analysis. Probiotic supplements probably reduce the incidence of diarrhea (RR 0.61 [0.43 to 0.87]; moderate certainty) and probably reduce cough or dyspnea compared to placebo/standard care (RR 0.37 [0.19 to 0.73]; moderate certainty). Probiotic supplements may improve composite endpoint measured by clinical escalation or mortality compared to placebo (RR 0.41 [0.18 to 0.93]; low certainty evidence); however, they may not significantly reduce the need for clinical escalation (RR 0.57 [0.31 to 1.07]; low certainty evidence) or mortality (RR 0.50 [0.20 to 1.29]; low certainty evidence). In addition, the probiotic supplement is associated with reduced adverse events (RR 0.62 [0.46 to 0.83]; moderate certainty).
Conclusion
Early probiotic supplement is a safe and effective adjunctive therapy that reduces the risk of symptoms and health care burden related to COVID-19 across all severity types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, Division of Digestive Care and Endoscopy, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
- Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
- Department of Anesthesia, McMaster University, Hamilton, Ontario, Canada.
- Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada.
ORCID-Profile: Julie Zhu, Tyler Pitre
Zitieren
APA
Zhu, J., Pitre, T., Ching, C., Zeraatkar, D., & Gruchy, S. (2023). Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: A systematic review and meta-analysis. PLOS ONE, 18(3), e0278356. https://doi.org/10.1371/journal.pone.0278356
Vancouver
Zhu J, Pitre T, Ching C, Zeraatkar D, Gruchy S. Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: A systematic review and meta-analysis. PLOS ONE. 2023;18(3):e0278356. doi:10.1371/journal.pone.0278356
BibTeX
@article{Zhu2023,
author = {Zhu, Julie and Pitre, Tyler and Ching, Carmen and Zeraatkar, Dena and Gruchy, Steven},
title = {Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: A systematic review and meta-analysis},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {3},
pages = {e0278356},
doi = {10.1371/journal.pone.0278356}
}
EUVIMED